Safety of Cabergoline for Prolactinoma in Pregnancy: A Systematic Review and Meta-Analysis.

IF 2.4 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Ananda Mohan Chakraborty, Ashu Rastogi
{"title":"Safety of Cabergoline for Prolactinoma in Pregnancy: A Systematic Review and Meta-Analysis.","authors":"Ananda Mohan Chakraborty, Ashu Rastogi","doi":"10.1111/cen.15304","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Prolactinoma is commonly treated with cabergoline, a dopamine D2 agonist. The present systematic review and meta-analysis aimed to assess the safety of cabergoline during pregnancy by examining outcomes of fetal loss, congenital malformations, preterm delivery, low birth weight, and change of tumour size post-gestation.</p><p><strong>Method: </strong>We conducted a systematic review as per PRISMA guidelines, focusing on pregnant patients with prolactinoma. Using the PICO model, we analyzed pregnancy outcomes in women continued cabergoline during gestation versus discontinuation at pregnancy diagnosis. Our methodologies included data extraction, study selection, and outcome analysis.</p><p><strong>Results: </strong>A total of 12 studies mentioning 1387 pregnancies with prolactinoma were included. Fetal loss occurred in 16.1% of cases, while congenital malformations were observed in 4.7%. The live birth rates among cabergoline users during gestation were lower compared to non-users [RR 0.81 (0.67-0.98, 95% CI); p = 0.03]. The congenital malformations [0.99 (95% CI: 0.93-1.07); p = 0.88], preterm birth [RR: 1.00 (95% CI: 0.93-1.07); p = 0.97] and low birth weight [RR: 1.02 (95% CI: 0.90-1.16); p = 0.71] showed no differences between the two groups.</p><p><strong>Conclusion: </strong>Cabergoline, when continued during pregnancy, is associated with a lower chance of live birth compared to discontinuation of pregnancy at diagnosis of pregnancy in women with prolactinoma. However, there was no increased risk of incident congenital malformation, preterm birth or low birth weight. The analysis suggests careful consideration of cabergoline use in pregnant women with prolactinoma.</p>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/cen.15304","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Prolactinoma is commonly treated with cabergoline, a dopamine D2 agonist. The present systematic review and meta-analysis aimed to assess the safety of cabergoline during pregnancy by examining outcomes of fetal loss, congenital malformations, preterm delivery, low birth weight, and change of tumour size post-gestation.

Method: We conducted a systematic review as per PRISMA guidelines, focusing on pregnant patients with prolactinoma. Using the PICO model, we analyzed pregnancy outcomes in women continued cabergoline during gestation versus discontinuation at pregnancy diagnosis. Our methodologies included data extraction, study selection, and outcome analysis.

Results: A total of 12 studies mentioning 1387 pregnancies with prolactinoma were included. Fetal loss occurred in 16.1% of cases, while congenital malformations were observed in 4.7%. The live birth rates among cabergoline users during gestation were lower compared to non-users [RR 0.81 (0.67-0.98, 95% CI); p = 0.03]. The congenital malformations [0.99 (95% CI: 0.93-1.07); p = 0.88], preterm birth [RR: 1.00 (95% CI: 0.93-1.07); p = 0.97] and low birth weight [RR: 1.02 (95% CI: 0.90-1.16); p = 0.71] showed no differences between the two groups.

Conclusion: Cabergoline, when continued during pregnancy, is associated with a lower chance of live birth compared to discontinuation of pregnancy at diagnosis of pregnancy in women with prolactinoma. However, there was no increased risk of incident congenital malformation, preterm birth or low birth weight. The analysis suggests careful consideration of cabergoline use in pregnant women with prolactinoma.

卡麦角林治疗妊娠催乳素瘤的安全性:一项系统综述和荟萃分析。
简介:催乳素瘤通常用卡麦角林(一种多巴胺D2激动剂)治疗。本系统综述和荟萃分析旨在通过检查胎儿丢失、先天性畸形、早产、低出生体重和妊娠后肿瘤大小变化的结局来评估卡麦角林在妊娠期间的安全性。方法:我们根据PRISMA指南对妊娠催乳素瘤患者进行了系统评价。使用PICO模型,我们分析了妊娠期间继续使用卡麦角林的妇女与妊娠诊断后停止使用卡麦角林的妇女的妊娠结局。我们的方法包括数据提取、研究选择和结果分析。结果:共纳入12项研究,涉及1387例泌乳素瘤孕妇。胎儿丢失占16.1%,先天性畸形占4.7%。妊娠期卡麦角林服用者的活产率低于非服用者[RR 0.81 (0.67-0.98, 95% CI);p = 0.03]。先天性畸形[0.99 (95% CI: 0.93-1.07);p = 0.88),早产(RR: 1.00(95%置信区间:0.93—-1.07);p = 0.97]和低出生体重[RR: 1.02 (95% CI: 0.90-1.16);P = 0.71]两组间差异无统计学意义。结论:在妊娠期间继续使用卡麦角林,与诊断为妊娠的泌乳素瘤妇女终止妊娠相比,其活产机会较低。然而,没有增加发生先天性畸形、早产或低出生体重的风险。该分析建议在患有催乳素瘤的孕妇中慎重考虑卡麦角林的使用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Endocrinology
Clinical Endocrinology 医学-内分泌学与代谢
CiteScore
6.40
自引率
3.10%
发文量
192
审稿时长
1 months
期刊介绍: Clinical Endocrinology publishes papers and reviews which focus on the clinical aspects of endocrinology, including the clinical application of molecular endocrinology. It does not publish papers relating directly to diabetes care and clinical management. It features reviews, original papers, commentaries, correspondence and Clinical Questions. Clinical Endocrinology is essential reading not only for those engaged in endocrinological research but also for those involved primarily in clinical practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信